Popular Filters
Trials for CAH Patients
Corticosteroid
CRN04894 for Congenital Adrenal Hyperplasia
Recruiting1 awardPhase 2
Morehead City, North Carolina
This trial is testing a new drug called CRN04894 in people with a genetic condition called classic congenital adrenal hyperplasia (CAH). The condition affects hormone production, and current treatments may not work well. The study will see if CRN04894 can safely and effectively help manage hormone levels by targeting the underlying cause of CAH.
Behavioural Intervention
Virtual Education Program for Congenital Adrenal Hyperplasia
Recruiting1 award6 criteria
Bethesda, Maryland
This trial tests if online lessons can help young people with CAH learn to manage their health as they transition to adult care. It aims to improve their knowledge, medication adherence, and appointment scheduling.
Corticosteroid
Chronocort for Congenital Adrenal Hyperplasia
Recruiting4 awardsPhase 3
Bethesda, Maryland
This trial is testing Chronocort, a medication for people aged 16 and over with Congenital Adrenal Hyperplasia (CAH). It aims to see if Chronocort can safely and effectively manage their hormone levels. Chronocort works by releasing hormones in a way that mimics the body's natural rhythm. Chronocort is a modified-release formulation of hydrocortisone designed to better mimic the body's natural cortisol circadian rhythm.
Corticosteroid
Crinecerfont for Congenital Adrenal Hyperplasia
Recruiting1 awardPhase 3
Queens, New York
This trial is testing a medication called crinecerfont to help children with a hormone disorder called CAH. The study will compare crinecerfont to another treatment over several months. The goal is to see if crinecerfont can safely and effectively balance their hormone levels.
Gene Therapy
Gene Therapy for Congenital Adrenal Hyperplasia
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial tests a new gene therapy called BBP-631, delivered by a virus through an IV, in adults with classic congenital adrenal hyperplasia. The goal is to see if it is safe and effective over several years. BBP-631 is a gene therapy delivered by a virus, similar to other gene therapies that have shown promise in treating adrenal disorders.
Corticosteroid
Tildacerfont for Congenital Adrenal Hyperplasia
Recruiting0 awardsPhase 2
Birmingham, Alabama
This trial is testing Tildacerfont to see if it can help adults with classic CAH reduce their steroid doses. The study will initially compare Tildacerfont to another treatment for several months, then allow all participants to use Tildacerfont for an extended period, with an optional longer-term extension. The goal is to find a safer way to manage CAH by lowering the need for high steroid doses. Tildacerfont has been studied in earlier trials for adults with classic congenital adrenal hyperplasia (CAH).
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.